Side-by-side comparison of AI visibility scores, market position, and capabilities
Global payments platform with €1T+ annual volume; single integration for 250+ payment methods across online and in-store for Netflix, Uber, and Spotify competing with Stripe.
Adyen is a global payments technology company providing a unified payments platform that enables businesses to accept payments in any payment method, in any currency, across online, in-app, and in-store channels — serving the world's largest enterprises including eBay, Netflix, Meta, Uber, Spotify, and McDonald's who need sophisticated, high-volume payment processing infrastructure. Listed on Euronext Amsterdam (AMS: ADYEN) and headquartered in Amsterdam, Adyen generates approximately €1.8 billion in net revenue and processes over €1 trillion in total payment volume annually.\n\nAdyen's single-platform approach — one integration, one contract, one reporting system for all global payment methods (Visa, Mastercard, American Express, PayPal, iDEAL, Alipay, WeChat Pay, and 250+ local methods) across all channels (e-commerce, iOS, Android, in-store POS terminals) — differentiates it from legacy payment processors that require separate integrations for different channels and geographies. The unified data model provides merchants with a global view of customer payment behavior across channels, enabling sophisticated fraud detection and personalized checkout experiences.\n\nIn 2025, Adyen is one of the most admired payments companies globally, having grown from startup to €50+ billion market cap in approximately 15 years by winning the payment infrastructure of the world's most sophisticated digital merchants. The company competes with Stripe (the other leading modern payments platform), Braintree (PayPal), and legacy processors (Worldpay, Fiserv) for enterprise payment processing. Adyen's 2025 strategy focuses on expanding its unified commerce platform (connecting online and offline customer data for retailers), growing financial services embedded finance offerings (Adyen for Platforms), and geographic expansion in Southeast Asia and Latin America.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.